109. American Cancer Society. Breast cancer facts & ;gures
2013–2014. Atlanta (GA): ACS; 2013.
110. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM,
Liu MC, et al. E;cacy and Safety of Neoadjuvant
Pertuzumab and Trastuzumab in Women with Locally
Advanced, In;ammatory, or Early HER2-Positive
Breast Cancer (NeoSphere): a randomised multicentre,
open-label, phase 2 trial. Lancet Oncol 2012;13: 25–32.
111. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya
K, Chin K, et al. Four-year survival rates for patients
with metastatic melanoma who received ipilimumab in
phase II clinical trials. Ann Oncol 2013;24:2174–80.
112. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ,
Ke;ord R, et al. Safety and tumor responses with
lambrolizumab (anti-PD- 1) in melanoma. N Engl J
Med 2013;369:134–44.
113. Ribas A, Hodi FS, Ke;ord R, Hamid O, Daud A,
Wolchok JD, et al. E;cacy and safety of the anti-PD- 1
monoclonal antibody MK-3475 in 411 patients (pts)
with melanoma (MEL). J Clin Oncol 2014;32:(suppl 5;
abstr LBA9000^).
114. Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB,
Balmanoukian AS, et al. Safety and clinical activity of
MK-3475 as initial therapy in patients with advanced
non-small cell lung cancer (NSCLC). J Clin Oncol
2014;32:(suppl 5; abstr 8007).
115. Seiwert T Y, Burtness B, Weiss J, Gluck I, Eder JP, Pai
SI, et al. A phase Ib study of MK-3475 in patients with
human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin
Oncol 2014;32:(suppl 5; abstr 6011).
116. Hodi FS, Sznol M, Kluger HM, McDermott DF,
Carvajal RD, Lawrence DP, et al. Long-term survival
of ipilimumab-naive patients (pts) with advanced
melanoma (MEL) treated with nivolumab (anti-PD- 1,
BMS-936558, ONO-4538) in a phase I trial. J Clin
Oncol 2014;32:(suppl 5; abstr 9002).
117. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR,
Chow LQM, Juergens RA, et al. First-line nivolumab
(anti-PD- 1; BMS-936558, ONO-4538) monotherapy
in advanced NSCLC: Safety, e;cacy, and correlation
of outcomes with PD-L1 status. J Clin Oncol
2014;32:(suppl 5; abstr 8024).
118. Brahmer JR, Horn L, Gandhi L, Spigel DR, Antonia SJ,
Rizvi NA, et al. Nivolumab (anti-PD- 1, BMS-936558,
ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity
by subgroup analysis. J Clin Oncol 2014;32:(suppl 5;
abstr 8112^).
119. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel
T, Harrison MR, et al. Nivolumab for metastatic renal
cell carcinoma (mRCC): Results of a randomized,
dose-ranging phase II trial. J Clin Oncol 2014;32:(suppl
5; abstr 5009).
120. Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS,
Loriot Y, et al. Inhibition of PD-L1 by MPDL3280A
and clinical activity in pts with metastatic urothelial
bladder cancer (UBC). J Clin Oncol 2014;32:(suppl 5;
abstr 5011).
121. Sznol M, Kluger HM, Callahan MK, Postow MA,
Gordon RA, Segal NH, et al. Survival, response
duration, and activity by BRAF mutation (MT)
status of nivolumab (NIVO, anti-PD- 1, BMS-936558,
ONO-4538) and ipilimumab (IPI) concurrent
therapy in advanced melanoma (MEL).J Clin Oncol
2014;32:(suppl 5; abstr LBA9003).
122. Puzanov I, Milhem MM, Andtbacka RHI, Minor
DR, Hamid O, Li A, et al. Primary analysis of a phase
1b multicenter trial to evaluate safety and e;cacy of
talimogene laherparepvec (T-VEC) and ipilimumab
(ipi) in previously untreated, unresected stage IIIB- IV
melanoma. J Clin Oncol 2014;32:(suppl 5; abstr 9029).
123. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran
K, et al. E;cacy and toxicity management of 19-28z
CAR T-cell therapy in B cell acute lymphoblastic
leukemia. Sci Transl Med 2014;6:224ra25.
124. Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew
A, Kalos M, et al. T cells engineered with a chimeric
antigen receptor (CAR) targeting CD19 (CTL019)
produce signi;cant in vivo proliferation, complete
responses and long-term persistence without Gvhd
in children and adults with relapsed, refractory ALL.
Blood 2013;122: 67.
125. Porter D, Kalos M, Frey NV, Grupp SA, Loren AW,
Jemison C, et al. Chimeric antigen receptor modi;ed
T cells directed against CD19 (CTL019 cells) have
long-term persistence and induce durable responses in
relapsed, refractory CLL. Blood 2013;122:4162.
126. Novartis highlights research on investigational,
personalized T-cell therapy CTL019 in patients with
forms of acute and chronic leukemia. [news release;
cited 2014 Jul 31]. Available from: http://www.novartis.
com/newsroom/media-releases/en/2013/1748415.
shtml.
127. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen
MC, Plesa G, et al. Mesothelin-speci;c chimeric
antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol
Res 2014;2: 112–20.
128. Maus MV, Grupp SA, Porter DL, June CH. Antibody-
modi;ed T cells: CARs take the front seat for
hematologic malignancies. Blood 2014;123:2625–35.
129. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu
P, Schwartzentruber DJ, et al. Cancer regression and
autoimmunity in patients a;er clonal repopulation
with antitumor lymphocytes. Science 2002;298:850– 4.
130.Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh
M, Hwu P, et al. Tumor-in;ltrating lymphocyte therapy
for melanoma: rationale and issues for further clinical
development. BioDrugs 2014 Jun 3. [Epub ahead of print].
131. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley
ME, et al. Cancer immunotherapy based on mutation-
speci;c CD4+ T cells in a patient with epithelial cancer.
Science 2014;344:641–5.
132. Hinrichs CS, Stevanovic S, Draper L, Somerville R,
Wunderlich J, Restifo NP, et al. HPV-targeted tumor-
in;ltrating lymphocytes for cervical cancer. J Clin
Oncol 2014;32:(suppl 5; abstr LBA3008).
REFERENCES
